Quick Answer
Rallybio Corp reported Operating Income Loss of -$33.06 million for the year ending 2025.
- Rallybio Corp showed an increase of +45.3% in Operating Income Loss from 2024 to 2025.
- This data is from Rallybio Corp's annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$4.66 million | Q3 2020: -$6.71 million | Q1 2021: -$12.82 million | Q2 2021: -$10.53 million | Q3 2021: -$9.98 million | Q1 2022: -$14.32 million | Q2 2022: -$17.62 million | Q3 2022: -$18.86 million | Q1 2023: -$18.37 million | Q2 2023: -$20.08 million | Q3 2023: -$19.36 million | Q1 2024: -$19.79 million | Q2 2024: -$17.04 million | Q3 2024: -$12.07 million | Q1 2025: -$9.67 million | Q2 2025: -$10.06 million | Q3 2025: -$6.93 million.
- Over the full 6 years of available data (2020 to 2025), Rallybio Corp's Operating Income Loss has declined by 30.7%.
- Historical annual values: Fiscal year 2025: -$33.06 million | Fiscal year 2024: -$60.50 million | Fiscal year 2023: -$78.93 million | Fiscal year 2022: -$67.88 million | Fiscal year 2021: -$45.65 million | Fiscal year 2020: -$25.30 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: